Navamedic launches new generic drug

Navamedic ASA (OSE: NAVA), the Norwegian pharmaceutical products company, today announced the launch of a new generic pharmaceutical product. Since 2011 the Company has been building a portfolio of generic drugs in the Nordic and Benelux markets.

The product now being launched is Montelukast Aspen, which is a drug used in the treatment of asthma and to relieve symptoms of seasonal allergies. Montelukast Aspen can replace MSD's Singulair. The new generic drug will be introduced across Navamedic's key markets.

Navamedic expects to launch additional generic drugs throughout 2013. The Company has a broad pipeline of new products currently under review by medicines authorities. Navamedic has been developing its portfolio of generic drugs over the last three years and expects to become a significant provider of generic drugs in the Nordic and Benelux markets over the next few years.

For further information, please call Olof Milveden, CEO, telephone +46 733 463 736 or Bjørn Lindholt, CFO, telephone +47 9300 6601.

Navamedic ASA is a Norwegian pharmaceutical products company, marketing and distributing more than 100 products in the Nordic and Benelux markets. The Company operates three business areas; Pharma Products, Medical Nutrition and Consumer Care based on its relationship with a number of pharmaceutical product manufacturers. Navamedic is listed on the Oslo Stock Exchange (ticker: NAVA).